Hastings Women’s Law Journal
Volume 11 | Number 1

Article 3

1-1-2000

Still Cloudy, with Little Chance of Clearing: FDA's
Proposed Rule on Structure/Function Claims for
Dietary Supplements
Michele Simon

Follow this and additional works at: https://repository.uchastings.edu/hwlj
Part of the Law and Gender Commons
Recommended Citation
Michele Simon, Still Cloudy, with Little Chance of Clearing: FDA's Proposed Rule on Structure/Function Claims for Dietary Supplements,
11 Hastings Women's L.J. 23 (2000).
Available at: https://repository.uchastings.edu/hwlj/vol11/iss1/3

This Commentary is brought to you for free and open access by the Law Journals at UC Hastings Scholarship Repository. It has been accepted for
inclusion in Hastings Women’s Law Journal by an authorized editor of UC Hastings Scholarship Repository. For more information, please contact
wangangela@uchastings.edu.

Still Cloudy, With Little Chance of Clearing:
FDA's Proposed Rule on Structure/Function

Claims for Dietary Supplements
Michele Simon*
Thanks to 'clarification' by federal regulators, consumers of dietary
supplements will now have better information when they seek to "improve
their absentmindedness" or "maintain their healthy intestinal flora." These
are just two examples of the permissible claims contained within the Food
and Drug Administration's (FDA) proposed rule, with the lofty title,
"Regulations on Statements Made for Dietary Supplements Concerning the
Effect of the Product on the Structure or Function of the Body."1 The rule
seeks to clarify the distinction made with the passage of the Dietary
Supplement Health and Education Act of 1994 for which types of health
claims are impermissible as drug claims, and which claims may be made as
related to the body's structure or function, the so-called, "structure/function
claims." According to William Shultz, the FDA's Deputy Commissioner
for Policy: "Consumers want access to dietary supplements, but also need
reliable information about the products they are consuming. By clarifying
for manufacturers what types of claims can and cannot be made on a
dietary supplement label, this new proposal helps consumers make more
informed and wiser choices." While clarification is sorely needed in this
arena, some of the FDA's examples are bound to keep manufacturers and
consumers alike at least as confused as before, if not more so.
*Michele Simon is a freelance writer specializing in food and nutrition policy. She teaches
"The Politics of Food" at John F. Kennedy University School of Law. She earned her law

degree from University of California, Hastings College of the Law in 1995 and a master's in
public health from Yale University in 1992. You can reach her at: msimon@igc.org.

1. 63 Fed. Reg. 23624, 23625 (1998) (to be codified at 21 C.F.R. § 101) (proposed April
29, 1998). All subsequent quotations within the text also come from the proposed rules.
Please see the Appendix to this commentary, which contains an edited version of the
proposed rules, for further support. Further and more definitive information may be found
in the FDA's final rules regulating structure/function claims on dietary supplements issued
on January 6, 2000. See Regulations on Statements Made for Dietary Supplements

Concerning the Effect of the Product on the Structure or Function of the Body, 65 Fed. Reg.
1000, 1000 (2000) (to be codified at 21 C.F.R. § 101).
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CAN THIS BE ANY CLEARER?
In the FDA's attempt to remove all references to "recognizable signs or
symptoms" of disease in dietary supplement labeling, an example of a
prohibited claim would be, "reduces joint pain," while allowable would be,
"improves absentmindedness." Some mental gymnastics are needed to
realize this probably doesn't mean the product makes one forget more.
Another silly example of an allowable claim in this category is, "inhibits
platelet aggregation." Is the average consumer really expected to
understand what this means and what the product could possibly be for?
Another of the FDA's criteria for determining disease claims is
whether the product claims to have a role in the body's response to a
disease or a vector of disease. Under the proposed rule, the FDA would not
permit claims that a product "supports the body's antiviral capabilities" or
"supports the body's ability to resist infection" because such claims involve
the body's ability to prevent or respond to infectious diseases. However, a
more general reference, such as "supports the immune system" would be
permitted. But isn't one of the main purposes of the immune system to
respond to infectious diseases?
But the winner for the most absurd example of a prohibited versus
allowable claim is this. Prohibited: "alleviates constipation;" allowable:
"helps maintain healthy intestinal flora." What the heck is intestinal flora?
Images of air freshener come to mind. While some manufacturers may use
such inside lingo, will this truly "help consumers make more informed and
wiser choices"?
A DISTINCTION WITHOUT A DIFFERENCE
The FDA specifically requested comment on the distinction between
maintaining normal function, the basis for an allowable structure/function
claim, and preventing or treating abnormal function, which is potentially a
disease claim. As the FDA admits: "This can be a difficult distinction
conceptually, especially if the only reason for maintaining normal function
is to prevent a specific disease or diseases associated with abnormal
function." Further, the FDA notes that "there can be disagreement about
the circumstances in which a reference to maintaining normal function
implies disease treatment or prevention." To put it mildly.
By way of example, under the proposed rule, "lowers cholesterol"
would be prohibited, while "helps maintain healthy cholesterol level"
would be permitted. Now, the FDA notes that cholesterol raises particularly
difficult issues and specifically requests comment in this area. But the
problem here relates to the broader issue which is really at the root of the
confusion and silly examples the FDA is proposing: for what purpose a
consumer is likely to turn to these products in the first place. While some
products may actually be intended for, and used for the prevention of
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certain health problems or diseases, other products are unlikely to be used
until a consumer is faced with an actual health problem. In the latter
situation, all this language about "maintaining" a healthy state becomes
irrelevant. If someone has been found to have high cholesterol levels and
turns to a dietary supplement, then reading "maintains healthy cholesterol
level" on the label will probably not make any substantive difference to
that consumer over the claim "lowers cholesterol levels" because the latter
is what the consumer seeks. It's quite unlikely that a person with healthy
cholesterol levels would take a product to help maintain those levels.
Further, chances are that any confusion will be cheerfully cleared up by a
helpful salesperson in the store. The FDA can say that dietary supplements
should not be used to treat health problems, but we must face the reality
that they are being used for this very purpose in some instances. This is
why trying to fashion a one-size fits all solution for an industry with very
different types of products does not work. For example, vitamin
supplements can and do serve a very different purpose than herbal
remedies. Perhaps the FDA would be better off going back to the drawing
board and making different rules for products with different purposes.
There is simply no getting around the reality of consumers turning to
dietary supplements for treatment-related purposes. The FDA's attempt to
bury its head in the sand and pretend this is not happening because
manufacturers are not allowed to label and market its products as such is
both irresponsible and futile. If the FDA is sincere in its desire to write a
rule which "helps consumers make more informed and wiser choices" than
facing this reality would be an important step in this direction.
APPENDIX
Regulations on Statements Made for Dietary Supplements Concerning the
Effect of the Product on the Structure or Function of the Body, 63 Fed.
Reg. 23624, 23625 (1998) (to be codified at 21 C.F.R. § 101) (proposed
April 29, 1998).
Wednesday, April 29, 1998
SUMMARY: The Food and Drug Administration (FDA) is proposing
regulations defining the types of statements that can be made concerning
the effect of a dietary supplement on the structure or function of the body.
The proposed regulations also establish criteria for determining when a
statement about a dietary supplement is a claim to diagnose, cure, mitigate,
treat, or prevent disease. This action is intended to provide direction to the
dietary supplement industry and to respond to guidance on this issue
provided by the Commission on Dietary Supplement Labels (the
Commission).
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PART 101--FOOD LABELING

§101.14 Health claims: general requirements.
(a) * * *
(6) Disease or health-related condition means any deviation from,
impairment of, or interruption of the normal structure or function of any
part, organ, or system (or combination thereof) of the body that is
manifested by a characteristic set of one or more signs or symptoms
(including laboratory or clinical measurements that are characteristic of a
disease), or a state of health leading to such deviation, impairment, or
interruption; except that diseases resulting from essential nutrient
deficiencies (e.g., scurvy, pellagra) are not included in this definition
(claims pertaining to such diseases are thereby not subject to this section or
§101.70).
3. Section 101.93, as currently in effect, is amended by revising the
section heading and by adding paragraphs (f) and (g) to read as follows:
§101.93 Certain types of statements for dietary supplements.
(f)Permitted structure/function statements. (1) Dietary supplement
labels or labeling may, subject to the requirements of this section, bear
statements that describe the role of a nutrient or dietary ingredient intended
to affect the structure or function in humans or that characterize the
documented mechanism by which a nutrient or dietary ingredient acts to
maintain such structure or function, but may not bear statements that are
disease claims under paragraph (g) of this section.
(g) Diseaseclaims. (1) Definition of disease. For purposes of 21 U.S.C.
343(r)(6), a "disease,, is any deviation from, impairment of, or interruption
of the normal structure or function of any part, organ, or system (or
combination thereof) of the body that is manifested by a characteristic set
of one or more signs or symptoms, including laboratory or clinical
measurements that are characteristic of a disease.
(2) Disease claims. FDA will find that a statement about a product
claims to diagnose, mitigate, treat, cure, or prevent disease (other than a
classical nutrient deficiency disease) under section 403(r)(6) of the act if it
meets one or more of the criteria listed in this paragraph (g)(2). In
determining whether a statement is a disease claim under these criteria,
FDA will consider the context in which the claim is presented. A statement
claims to diagnose, mitigate, treat, cure, or prevent disease if it claims,
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explicitly or implicitly, that the product:
(i) Has an effect on a specific disease or class of diseases;
(ii) Has an effect, using scientific or lay terminology, on one or more
signs or symptoms that are recognizable to health care professionals or
consumers as being characteristic of a specific disease or of a number of
different specific diseases;
(iii) Has an effect on a consequence of a natural state that presents a
characteristic set of signs or symptoms recognizable to health care
professionals or consumers as constituting an abnormality of the body;
(iv) Has an effect on disease through one or more of the following
factors:
(A) The name of the product;
(B) A statement about the formulation of the product, including a claim
that the product contains an ingredient that has been regulated by FDA as a
drug and is well known to consumers for its use in preventing or treating a
disease;
(C) Citation of the title of a publication or reference, if the title refers to
a disease use;
(D) Use of the term "disease" or "diseased"; or
(E) Use of pictures, vignettes, symbols, or other means;
(v) Belongs to a class of products that is intended to diagnose, mitigate,
treat, cure, or prevent a disease;
(vi) Is a substitute for a product that is a therapy for a disease;
(vii) Augments a particular therapy or drug action;
(viii) Has a role in the body's response to a disease or to a vector of
disease;
(ix) Treats, prevents, or mitigates adverse events associated with a
therapy for a disease and manifested by a characteristic set of signs or
symptoms; or
(x) Otherwise suggests an effect on a disease or diseases.

